CO2021011090A2 - Composiciones útiles en el tratamiento de la enfermedad de krabbe - Google Patents
Composiciones útiles en el tratamiento de la enfermedad de krabbeInfo
- Publication number
- CO2021011090A2 CO2021011090A2 CONC2021/0011090A CO2021011090A CO2021011090A2 CO 2021011090 A2 CO2021011090 A2 CO 2021011090A2 CO 2021011090 A CO2021011090 A CO 2021011090A CO 2021011090 A2 CO2021011090 A2 CO 2021011090A2
- Authority
- CO
- Colombia
- Prior art keywords
- treatment
- useful compositions
- krabbe disease
- krabbe
- administration
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2468—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on beta-galactose-glycoside bonds, e.g. carrageenases (3.2.1.83; 3.2.1.157); beta-agarase (3.2.1.81)
- C12N9/2471—Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/30—Vector systems having a special element relevant for transcription being an enhancer not forming part of the promoter region
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01046—Galactosylceramidase (3.2.1.46)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962810708P | 2019-02-26 | 2019-02-26 | |
| US201962817482P | 2019-03-12 | 2019-03-12 | |
| US201962877707P | 2019-07-23 | 2019-07-23 | |
| US201962916652P | 2019-10-17 | 2019-10-17 | |
| PCT/US2020/019794 WO2020176562A1 (en) | 2019-02-26 | 2020-02-26 | Compositions useful in treatment of krabbe disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2021011090A2 true CO2021011090A2 (es) | 2021-09-09 |
Family
ID=69941503
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2021/0011090A CO2021011090A2 (es) | 2019-02-26 | 2021-08-24 | Composiciones útiles en el tratamiento de la enfermedad de krabbe |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20220118108A1 (https=) |
| EP (1) | EP3931337A1 (https=) |
| JP (2) | JP2022525848A (https=) |
| KR (1) | KR20210132095A (https=) |
| CN (1) | CN114040980A (https=) |
| AU (1) | AU2020229772A1 (https=) |
| BR (1) | BR112021016566A2 (https=) |
| CA (1) | CA3130055A1 (https=) |
| CL (1) | CL2021002248A1 (https=) |
| CO (1) | CO2021011090A2 (https=) |
| IL (1) | IL285776A (https=) |
| MX (1) | MX2021010266A (https=) |
| PE (1) | PE20212072A1 (https=) |
| SG (1) | SG11202108480UA (https=) |
| TW (1) | TW202045728A (https=) |
| WO (1) | WO2020176562A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3177924A1 (en) * | 2020-05-12 | 2021-11-18 | The Trustees Of The University Of Pennsylvania | Compositions useful in treatment of krabbe disease |
| KR20230170022A (ko) * | 2021-04-12 | 2023-12-18 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | 척수 및 연수 근위축증(sbma) 치료에 유용한 조성물 |
| EP4695389A2 (en) * | 2023-04-10 | 2026-02-18 | M6P Therapeutics, Inc. | Compositions comprising modified human galactocerebrosidase |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
| US5436146A (en) | 1989-09-07 | 1995-07-25 | The Trustees Of Princeton University | Helper-free stocks of recombinant adeno-associated virus vectors |
| US6268213B1 (en) | 1992-06-03 | 2001-07-31 | Richard Jude Samulski | Adeno-associated virus vector and cis-acting regulatory and promoter elements capable of expressing at least one gene and method of using same for gene therapy |
| US5869305A (en) | 1992-12-04 | 1999-02-09 | The University Of Pittsburgh | Recombinant viral vector system |
| US6204059B1 (en) | 1994-06-30 | 2001-03-20 | University Of Pittsburgh | AAV capsid vehicles for molecular transfer |
| US6093570A (en) | 1995-06-07 | 2000-07-25 | The University Of North Carolina At Chapel Hill | Helper virus-free AAV production |
| US5741683A (en) | 1995-06-07 | 1998-04-21 | The Research Foundation Of State University Of New York | In vitro packaging of adeno-associated virus DNA |
| WO1998046728A1 (en) | 1997-04-14 | 1998-10-22 | Cell Genesys, Inc. | Methods for increasing the efficiency of recombinant aav product |
| WO1999061643A1 (en) | 1998-05-27 | 1999-12-02 | University Of Florida | Method of preparing recombinant adeno-associated virus compositions by using an iodixananol gradient |
| ES2340230T3 (es) | 1998-11-10 | 2010-05-31 | University Of North Carolina At Chapel Hill | Vectores viricos y sus procedimientos de preparacion y administracion. |
| PT1916258E (pt) | 1999-08-09 | 2014-07-29 | Genzyme Corp | Aumento da expressão de uma sequência nucleotídica heteróloga de cadeia simples a partir de vectores virais recombinantes por concepção da sequência de maneira que esta forme pares de bases intracadeia |
| US7201898B2 (en) | 2000-06-01 | 2007-04-10 | The University Of North Carolina At Chapel Hill | Methods and compounds for controlled release of recombinant parvovirus vectors |
| NZ532635A (en) | 2001-11-13 | 2007-05-31 | Univ Pennsylvania | A method of identifying unknown adeno-associated virus (AAV) sequences and a kit for the method |
| AU2003274397A1 (en) | 2002-06-05 | 2003-12-22 | University Of Florida | Production of pseudotyped recombinant aav virions |
| US8005620B2 (en) | 2003-08-01 | 2011-08-23 | Dna Twopointo Inc. | Systems and methods for biopolymer engineering |
| EP1660970A4 (en) | 2003-08-01 | 2007-02-14 | Dna Twopointo Inc | SYSTEMS AND METHODS FOR BIOPOLYMER TECHNOLOGY |
| CN1856576B (zh) | 2003-09-30 | 2011-05-04 | 宾夕法尼亚州立大学托管会 | 腺伴随病毒(aav)进化支、序列、含有这些序列的载体及它们的应用 |
| WO2006110689A2 (en) | 2005-04-07 | 2006-10-19 | The Trustees Of The University Of Pennsylvania | Method of increasing the function of an aav vector |
| EP1777906A1 (en) | 2005-06-09 | 2007-04-25 | Matsushita Electric Industrial Co., Ltd. | Amplitude error compensating apparatus and orthogonality error compensating apparatus |
| US7588772B2 (en) | 2006-03-30 | 2009-09-15 | Board Of Trustees Of The Leland Stamford Junior University | AAV capsid library and AAV capsid proteins |
| PL3252161T3 (pl) * | 2007-06-06 | 2022-03-07 | Genzyme Corporation | Terapia genowa dla lizosomalnych chorób spichrzeniowych |
| WO2010138263A2 (en) | 2009-05-28 | 2010-12-02 | University Of Massachusetts | Novel aav 's and uses thereof |
| US20130023033A1 (en) | 2010-03-29 | 2013-01-24 | The Trustees Of The University Of Pennsylvania | Pharmacologically induced transgene ablation system |
| US8927514B2 (en) | 2010-04-30 | 2015-01-06 | City Of Hope | Recombinant adeno-associated vectors for targeted treatment |
| FR2977562B1 (fr) | 2011-07-06 | 2016-12-23 | Gaztransport Et Technigaz | Cuve etanche et thermiquement isolante integree dans une structure porteuse |
| EA030305B1 (ru) * | 2012-08-07 | 2018-07-31 | КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. | Животная модель болезни краббе |
| US9719106B2 (en) * | 2013-04-29 | 2017-08-01 | The Trustees Of The University Of Pennsylvania | Tissue preferential codon modified expression cassettes, vectors containing same, and uses thereof |
| BR112017005892A2 (pt) | 2014-09-24 | 2017-12-12 | Hope City | variantes de vetor de vírus adeno-associado para edição de genoma de alta eficácia e métodos da mesma |
| US10195746B2 (en) | 2014-09-26 | 2019-02-05 | Teradyne, Inc. | Grasping gripper |
| HK1256341A1 (zh) * | 2015-05-15 | 2019-09-20 | 明尼苏达大学董事会 | 用於治疗性递送到中枢神经系统的腺相关物 |
| HK1257801A1 (zh) * | 2015-10-28 | 2019-11-01 | 宾夕法尼亚州大学信托人 | 用於基因治疗的腺伴随病毒载体的鞘内给药 |
| US12599636B2 (en) * | 2017-01-20 | 2026-04-14 | University of Pittsburgh—of the Commonwealth System of Higher Education | Treatment of Krabbe disease with umbilical cord blood transplantion (UCBT) and increased galactocerebrosidase (GALC) expression |
| JP7455579B2 (ja) * | 2017-02-28 | 2024-03-26 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 新規アデノ随伴ウイルス（ａａｖ）クレードｆベクター及びその用途 |
| WO2018160852A1 (en) | 2017-03-03 | 2018-09-07 | Cook Medical Technologies, LLC | Rapid exchange multiple catheter system |
| KR102709597B1 (ko) * | 2017-10-03 | 2024-09-26 | 프리베일 테라퓨틱스, 인크. | 리소좀 장애를 위한 유전자 요법 |
-
2020
- 2020-02-26 TW TW109106249A patent/TW202045728A/zh unknown
- 2020-02-26 US US17/433,195 patent/US20220118108A1/en active Pending
- 2020-02-26 PE PE2021001391A patent/PE20212072A1/es unknown
- 2020-02-26 EP EP20713474.3A patent/EP3931337A1/en active Pending
- 2020-02-26 JP JP2021549986A patent/JP2022525848A/ja active Pending
- 2020-02-26 CA CA3130055A patent/CA3130055A1/en active Pending
- 2020-02-26 MX MX2021010266A patent/MX2021010266A/es unknown
- 2020-02-26 BR BR112021016566A patent/BR112021016566A2/pt unknown
- 2020-02-26 WO PCT/US2020/019794 patent/WO2020176562A1/en not_active Ceased
- 2020-02-26 AU AU2020229772A patent/AU2020229772A1/en active Pending
- 2020-02-26 SG SG11202108480UA patent/SG11202108480UA/en unknown
- 2020-02-26 KR KR1020217029570A patent/KR20210132095A/ko active Pending
- 2020-02-26 CN CN202080017113.6A patent/CN114040980A/zh active Pending
-
2021
- 2021-08-22 IL IL285776A patent/IL285776A/en unknown
- 2021-08-24 CO CONC2021/0011090A patent/CO2021011090A2/es unknown
- 2021-08-25 CL CL2021002248A patent/CL2021002248A1/es unknown
-
2024
- 2024-11-29 JP JP2024208739A patent/JP2025032175A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022525848A (ja) | 2022-05-20 |
| KR20210132095A (ko) | 2021-11-03 |
| US20220118108A1 (en) | 2022-04-21 |
| JP2025032175A (ja) | 2025-03-11 |
| BR112021016566A2 (pt) | 2021-11-03 |
| PE20212072A1 (es) | 2021-10-26 |
| CL2021002248A1 (es) | 2022-03-04 |
| WO2020176562A1 (en) | 2020-09-03 |
| SG11202108480UA (en) | 2021-09-29 |
| CN114040980A (zh) | 2022-02-11 |
| AU2020229772A1 (en) | 2021-08-26 |
| MX2021010266A (es) | 2021-09-23 |
| IL285776A (en) | 2021-10-31 |
| TW202045728A (zh) | 2020-12-16 |
| EP3931337A1 (en) | 2022-01-05 |
| CA3130055A1 (en) | 2020-09-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2021011090A2 (es) | Composiciones útiles en el tratamiento de la enfermedad de krabbe | |
| MX2019008755A (es) | Variantes de hsd17b13 y usos de las mismas. | |
| CL2020001360A1 (es) | Cápsides variantes de virus adenoasociados y su uso para inhibir la angiogénesis. | |
| MX2024006041A (es) | Celulas t modificadas y metodos para hacer y usar las mismas. | |
| CL2020000666A1 (es) | Agentes de iarn y composiciones para inhibir la expresión de la angiopoyetina tipo 3 (angptl3) y métodos de uso. | |
| CR20200165A (es) | Variantes de cápsides de virus adenoasociados y métodos de uso de estas | |
| MX2019009720A (es) | Metodos y composiciones para la transferencia de genes a traves de la vasculatura. | |
| CL2018003196A1 (es) | Cápsides variantes de virus adenoasociados y métodos de uso de estas. | |
| CO2021017692A2 (es) | Partículas virales modificadas y usos de estas | |
| MX2020003888A (es) | Anticuerpos terapeuticos postraduccionalmente modificados completamente humanos. | |
| CO2018005361A2 (es) | Formulaciones inyectables de toxina botulínica y sus métodos de uso que poseen efecto terapéutico o cosmético de larga duración | |
| MX2017008504A (es) | Vacuna para enfermedad de newcastle y de bursitis infecciosa (nd-ibd) en vector de hvt mejorada. | |
| CL2020000019A1 (es) | Agentes de iarn para la inhibición de la expresión de alfa-enac y métodos de uso. | |
| ECSP14016014A (es) | Miméticos de apelina sintéticos para el tratamiento de insuficiencia cardíaca | |
| MX2021007241A (es) | Acido ribonucleico (arn) que codifica para una proteina. | |
| MX2022003758A (es) | Composiciones para el cuidado bucal que comprenden acido beta de lupulo y aminoacido. | |
| CL2023001650A1 (es) | Tratamiento de la enfermedad de danon | |
| CL2012000447A1 (es) | Composición o vacuna que comprende un vector viral de un paramixovirus aviar 8 (apmv-8) recombinante; método para producir dicho vector; y uso para preparar medicamento útil para inducir una respuesta inmunológica. | |
| MX2020005663A (es) | Terapia genica para mucopolisacaridosis iii a. | |
| MX2025004075A (es) | Vacunas para circovirus porcino tipo 3 (pcv3), y produccion y sus usos | |
| CL2023001876A1 (es) | Proteínas de la cápside viral con especificidad para las células del tejido cardiaco | |
| CA2917584C (en) | Genetically stable oncolytic rna virus, method of manufacturing and use thereof | |
| BR112017013270A2 (pt) | ?composição de vacina contra vírus da dengue, métodos para induzir uma resposta imune contra dengue, para reduzir a probabilidade de infecção por dengue, ou prevenir ou atenuar os sintomas da mesma, e, uso de uma composição de vacina contra vírus da dengue?. | |
| Summerfield | Factors involved in type I interferon responses during porcine virus infections | |
| PE20201166A1 (es) | Metodos y composiciones para tratar enfermedades pulmonares cronicas |